Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRISDELLE vs LUVOX CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.
Selective serotonin reuptake inhibitor (SSRI); increases serotonin availability in the synaptic cleft by blocking serotonin reuptake transporters (SERT).
FDA-approved: Treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause.,Off-label: Management of depression, anxiety disorders, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder.
Obsessive-compulsive disorder (OCD),Social anxiety disorder,Panic disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
8 mg orally once daily, taken at bedtime.
100-300 mg orally once daily at bedtime
Terminal elimination half-life is approximately 9-11 hours for paroxetine (the active ingredient in Brisdelle). This supports once-daily dosing; steady-state is achieved within 7-14 days.
The terminal elimination half-life is approximately 15-20 hours after single doses and 17-26 hours after multiple doses. This supports once-daily dosing, with steady-state achieved within 1-2 weeks.
Extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6. Metabolites are glucuronidated and excreted renally.
Primarily hepatic via CYP2D6; undergoes extensive first-pass metabolism; major metabolites are glucuronide conjugates.
Primarily renal excretion as metabolites; approximately 60% of a radiolabeled dose is recovered in urine and 30% in feces over 10 days. Less than 1% excreted unchanged.
Approximately 94% of a dose is excreted in urine, with less than 4% as unchanged drug. The remainder is eliminated in feces. Renal excretion of metabolites accounts for the majority of elimination.
Approximately 95% bound to plasma proteins, primarily to albumin and alpha-1 acid glycoprotein.
Approximately 80% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of distribution is about 3-28 L/kg (mean ~13 L/kg), indicating extensive tissue distribution.
The apparent volume of distribution is approximately 5-9 L/kg, indicating extensive tissue distribution beyond plasma volume.
Oral bioavailability is approximately 50-100% due to extensive first-pass metabolism; absolute bioavailability is about 50% for the immediate-release formulation.
Oral bioavailability is approximately 50-70% due to first-pass metabolism. Administration with food may slightly delay absorption but does not significantly alter the extent of absorption.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥ 30 m L/min). For severe renal impairment (Cr Cl < 30 m L/min) or end-stage renal disease, not recommended due to lack of data.
No specific dose adjustment required; use caution in severe renal impairment (Cr Cl < 30 m L/min) and consider lower starting dose.
Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate hepatic impairment (Child-Pugh B): maximum dose 4 mg orally once daily. Severe hepatic impairment (Child-Pugh C): contraindicated.
Child-Pugh Class A: 50 mg/day; Class B: 25 mg/day; Class C: not recommended.
Not approved for use in pediatric patients; safety and efficacy not established.
Not approved for patients under 18 years.
For patients >65 years, start with 4 mg orally once daily at bedtime; may increase to 8 mg once daily based on response and tolerability. Monitor closely for sedation and falls.
Initiate at 50 mg/day; titrate slowly to a maximum of 150 mg/day.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality risk in young adults,Serotonin syndrome with concurrent serotonergic drugs,Bone fractures risk,Sexual dysfunction,Abnormal bleeding risk,Angle-closure glaucoma risk,Hyponatremia in elderly or volume-depleted patients,Discontinuation syndrome upon abrupt withdrawal,Pregnancy: Potential harm to neonates (persistent pulmonary hypertension, serotonin syndrome),Lactation: Excreted in breast milk
Serotonin syndrome,Risk of bleeding with NSAIDs/aspirin,Activation of mania/hypomania,Seizure risk,Angle-closure glaucoma risk,Sexual dysfunction,Withdrawal symptoms on discontinuation
Concomitant use with MAOIs (or within 14 days of MAOI discontinuation),Concomitant use with thioridazine,Concomitant use with pimozide,Hypersensitivity to paroxetine or any component,Pregnancy (especially third trimester) due to risk of neonatal complications
Concomitant use with MAOIs or within 14 days of MAOI discontinuation,Concomitant use with pimozide or thioridazine,Known hypersensitivity to fluvoxamine
Avoid alcohol due to additive central nervous system depression. No specific food interactions; take without regard to meals.
No specific dietary restrictions. Grapefruit and grapefruit juice may increase fluvoxamine levels; avoid large quantities. Limit caffeine intake, as fluvoxamine may decrease caffeine clearance and increase stimulant effects.
Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses greater than human therapeutic doses. In humans, retrospective studies suggest a small increased risk of congenital heart defects (primarily ventricular septal defects) with first-trimester exposure. Third-trimester exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and neonatal withdrawal syndrome (respiratory distress, feeding difficulties, jitteriness).
First trimester: Epidemiologic studies have not consistently demonstrated an increased risk of major congenital anomalies; however, some studies suggest a small increased risk of cardiovascular malformations (e.g., ventricular septal defect) with maternal use of SSRIs overall. Fluvoxamine has limited data but is considered low risk. Second and third trimesters: Late pregnancy exposure may be associated with persistent pulmonary hypertension of the newborn (PPHN) (absolute risk about 1-2 per 1000), preterm birth, and transient neonatal adaptation syndrome (irritability, tachypnea, poor feeding) requiring monitoring. Neonatal withdrawal syndrome (serotonin discontinuation syndrome) may occur.
Paroxetine is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.5-0.7. Estimated infant dose is 1-2% of maternal weight-adjusted dose. No adverse effects have been consistently reported in breastfed infants, but caution is advised due to potential for serotonin-related effects. Benefits versus risks should be assessed.
Fluvoxamine is excreted into breast milk with an M/P ratio of approximately 0.29. Relative infant dose is estimated at 1.5-2% of maternal weight-adjusted dose. Cases of adverse effects in breastfed infants (e.g., irritability, poor feeding, sedation) are rare. Breastfeeding is generally considered acceptable with monitoring for infant neurobehavioral changes.
No specific dose adjustment is recommended solely due to pregnancy; however, pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) may lead to decreased drug levels. Clinical monitoring and dose titration based on therapeutic response and tolerability are advised. Avoid abrupt discontinuation to prevent withdrawal effects.
No routine dose adjustment is required for fluvoxamine during pregnancy. However, due to increased volume of distribution and enhanced hepatic metabolism (CYP1A2, CYP2D6) in pregnancy, some patients may require dose adjustments to maintain efficacy; therapeutic drug monitoring is not standard but consider checking trough levels. Initiate at lowest effective dose and titrate based on clinical response. Postpartum: Reduce dose pre-conception levels if increased during pregnancy to avoid toxicity.
BRISDELLE (paroxetine mesylate) is a selective serotonin reuptake inhibitor (SSRI) indicated for vasomotor symptoms (VMS) in menopause. It is the only non-hormonal therapy FDA-approved for moderate to severe VMS. Dosing starts at 7.5 mg once daily, typically at bedtime to minimize daytime sedation. Avoid concurrent use with MAOIs, other SSRIs/SNRIs, or strong CYP2D6 inhibitors (e.g., paroxetine itself). Monitor for serotonin syndrome, especially with triptans or linezolid. Discontinue gradually to avoid withdrawal symptoms. Note that paroxetine is pregnancy category D; use effective contraception.
LUVOX CR is an extended-release formulation of fluvoxamine, an SSRI approved for OCD. Dosing: start 100 mg at bedtime, titrate by 50 mg weekly up to 300 mg. Avoid abrupt discontinuation due to withdrawal symptoms. Monitor for serotonin syndrome, especially with concomitant serotonergic drugs. CR tablets must be swallowed whole; do not crush or chew.
Take BRISDELLE at bedtime to reduce daytime drowsiness.,Do not crush or chew the capsule; swallow whole.,It may take 2–4 weeks to see full benefit for hot flashes.,Avoid alcohol as it can increase sedation.,Do not stop suddenly; taper under medical guidance.,Report any suicidal thoughts, worsening depression, or unusual behavior changes.,Contact doctor if you experience severe headache, nausea, or rapid heartbeat (serotonin syndrome).,Store at room temperature away from moisture and heat.
Take LUVOX CR once daily at bedtime to minimize daytime sedation.,Swallow the tablet whole; do not crush, chew, or cut it.,May take 2-4 weeks for therapeutic effect; consistent adherence is important.,Do not stop taking abruptly; consult your doctor before discontinuing.,Avoid alcohol, as it may increase drowsiness and risk of adverse effects.,Report any suicidal thoughts, unusual mood changes, or serotonin syndrome symptoms (e.g., agitation, hallucinations, fever, rapid heart rate).,Use caution when driving or operating machinery until you know how LUVOX affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRISDELLE vs LUVOX CR, answered by our medical review team.
BRISDELLE is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.. LUVOX CR is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); increases serotonin availability in the synaptic cleft by blocking serotonin reuptake transporters (SERT).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRISDELLE and LUVOX CR depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRISDELLE is: 8 mg orally once daily, taken at bedtime.. The standard adult dose of LUVOX CR is: 100-300 mg orally once daily at bedtime. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRISDELLE and LUVOX CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRISDELLE is classified as Category C. Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses grea. LUVOX CR is classified as Category C. First trimester: Epidemiologic studies have not consistently demonstrated an increased risk of major congenital anomalies; however, some studies suggest a small increased risk of c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.